Back to results
US 2026/0159489 A1Published application
Deuterium-Enriched 6-Carboxy-2-(3,5-Dichlorophenyl)Benzoxazoles for Treatment of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Polyneuropathy (ATTR-PN), and Related Diseases
OwnerDaljit Singh Dhanoainventor
Life of this patent
Estimating the term…
Abstract
The present invention is concerned with novel deuterium-enriched compounds of the general chemical structural formula I, and pharmaceutically acceptable salts, compositions, and methods of use thereof, wherein, R is independently deuterium (D), hydrogen (H) atom. Compounds of general chemical structure I are stabilizers of the Transthyretin (TTR) protein and are useful in the treatment of Transthyretin Amyloidosis (ATTR) and related diseases.
Claims13
A deuterium-enriched compound selected from the group consisting of:
- (a) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic acid-d,
- (b) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic acid,
- (c) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-7-d acid-d,
- (d) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-7-d acid,
- (e) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-4,7-d2 acid-d,
- (f) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-4,7-d2 acid,
- (g) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-4,5,7-d3 acid-d,
- (h) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-4,5,7-d3 acid,
- (j) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-4-d1 acid-d,
- (k) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-4-d acid,
- (l) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-5,7-d2 acid-d,
- (m) 2-(3,5-dichlorophenyl-2,4,6-d3)-1,3-benzoxazole-6-carboxylic-5,7-d2 acid,
9 more elements
Dependencies are inferred from the claim text.